Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült Államok4. fázis

Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension

A legfontosabb adatok

Ki végzi
Oregon Health and Science University
Hol
Honolulu és Portland (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
4. fázis
Résztvevők
20 fő, tervezett
Kezdés
2026. dec. 1.
Várható befejezés
2028. nov. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Sotatercept
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 34 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥ 18 years
  • Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum mean PA pressure of 20 mmHg, PVR of ≥ 2 Wood units and pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of Meth-APAH as defined by patient verbally confirming exposure or having positive toxicology testing for methamphetamine within 5 years of PAH diagnosis
  • Symptomatic PAH classified as WHO FC II or III
  • Diagnosis of PAH within 12 months of screening and on stable doses of a ERA and PDE5i combination of background PAH therapies and diuretics (if any) for at least 90 days prior to screening
  • 6MWD ≥ 150 m completed at screening visit
  • Females of childbearing potential must meet the following criteria: Have 2 negative urine or serum pregnancy tests as verified by the investigator during the Screening Period; Agree to ongoing pregnancy testing (either urine or serum) during the course of the study and until 8 weeks after the last dose of the study drug; If sexually active with a male partner, use highly effective contraception without interruption for at least 28 days prior to starting the investigational product AND agree to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment; Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
  • Male participants must meet the following criteria: Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy; Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
  • Ability to adhere to study visit schedule and understand and comply with all protocol requirements
  • Ability to understand and provide documented informed consent

Ki nem vehet részt

  • Currently enrolled in or have completed any other investigational product study within 30 days for small-molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented informed consent
  • Pulmonary function test values of forced vital capacity < 60% predicted within 1 year prior to the Screening Visit
  • Stopped receiving any PH chronic general supportive therapy (e.g., diuretics, oxygen, anticoagulants, and digoxin) within 60 days prior to the Screening Visit
  • Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the Screening Visit or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)
  • History of atrial septostomy within 180 days prior to the Screening Visit
  • Coronary artery disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months prior to the Screening Visit
  • Cerebrovascular accident within 3 months prior to the Screening Visit
  • Acutely decompensated left heart failure within 30 days prior to the Screening Visit, as per investigator assessment
  • Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, and vasopressin) within 30 days prior to the Screening Visit
  • Active malignancy with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or prostate cancer that is not currently or expected, during the study, to be treated with radiation therapy, chemotherapy, and/or surgical intervention, or hormonal treatment
  • Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis- associated PAH, collagen vascular disease- associated PAH, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis
  • Uncontrolled systemic hypertension as evidenced by sitting systolic BP > 180 mmHg or sitting diastolic BP > 110 mmHg during the Screening Visit after a period of rest
  • Known allergic reaction to sotatercept (ACE-011), its excipients, or luspatercept
  • History of pneumonectomy
  • History of known pericardial constriction
  • History of restrictive cardiomyopathy
  • Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
  • Hgb at screening above gender-specific ULN, per local laboratory test
  • Any of the following clinical laboratory values at the Screening Visit: eGFR < 30 mL/min/1.73 m2 (as defined by MDRD equation), serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels > 3 × ULN, platelet count < 50,000/mm3 (< 50.0 × 109/L)
  • Personal or family history of long QT syndrome or sudden cardiac death
  • Left ventricular ejection fraction < 50% documented by a historical ECHO or cardiac MRI within the last 12 months prior to screening (if there is more than one assessment of LVEF, the value from the most recent measurement should be used in assessing eligibility)
  • Diagnosis of PH WHO Groups 2, 3, 4, or 5
  • Baseline systolic BP < 90 mmHg at screening
  • Pregnant or breastfeeding women
  • Untreated more than mild obstructive sleep apnea

Helyszínek itt: Egyesült Államok

  • The Queen's Medical CenterHonolulu, Egyesült ÁllamokContact: Gehan Devendra, MDToborzás még nem indult
  • Oregon Health Science UniversityPortland, Egyesült ÁllamokContact: Allyson Knapper, MDToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to find out whether sotatercept, an FDA-approved medication for people with pulmonary arterial hypertension (PAH), can improve health outcomes for people with PAH due to use of methamphetamine. The main question it aims to answer is whether sotatercept added to standard background therapy and addiction medicine services will improve treatment response as measured by:

A teljes eredeti leírásKevesebb

* Echocardiographic measurements of pulmonary hypertension * Change in 6-minute walk distance (6MWD) * Change in categorization of disease (World Health Organization Functional Class, WHO FC) * Quality of life improvements

Participants will need to adhere to their standard PAH therapy as well as the prescribed sotatercept, as well as actively engaging with addiction medicine services. They will complete the following activities:

* Physical exam * Labs including drug screening * Pulmonary function testing (PFT) * Exercise testing (6MWD) * Echocardiography * Right heart catheterization (RHC) * Questionnaires related to their disease

Participants will be in the study for about six months.

A vizsgálat csoportja

  • Sotatercept with addiction medicine servicesA vizsgált kezelés

    Kezelés: Sotatercept

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Methamphetamine-Associated PAH: Early Therapy With Sotatercept - Feasibility and Outcomes in Clinical Use Study (METH-FOCUS)
A regiszteradat frissítve
2026. november 16.